Newswise partners with NCI to create comprehensive site for cancer research news

Newswise has recently partnered with the National Cancer Institute (NCI) to create a comprehensive site for cancer research news and experts - the Cancer News Source. NCI and other leaders in cancer research provide the content, creating a site that contains the most up-to-date information directly from the source. The Cancer News Source provides access for journalists, communicators, and public users to monitor the latest cancer news in a one-stop-shop. Newswise distributes a complimentary Cancer Wire each week with the latest cancer news content.

"The Cancer News Source collaboration between NCI and Newswise is a chance for the cancer community to share our stories of cancer research in one place - from start to finish," describes Rick Borchelt, Special Assistant for Public Affairs at NCI about his vision for this project. "We envision this as a place where the research community can post stories about basic research, research breakthroughs, patient journeys and the background that goes into scientific research. There is value in gathering the cancer research community's stories into one location trusted by reporters. The Cancer News Source will fill a need in the community and allow us to broaden outreach to new and important audiences."

Jessica Johnson, Newswise CEO, will be at the PAN Conference in Denver, CO from April 24-27. We invite anyone interested to learn more about Newswise or the Cancer News Source to meet with her at the conference. The communications officers from NCI will present the collaboration at the meeting, and discuss cancer center participation.

While the primary audience for the Cancer News Source is journalists, there are advantages for the communications community as well. Communications and public relations officers benefit from staying informed of what other organizations are doing, and now an overview of cancer news is easily accessible when they subscribe to the weekly Cancer Wire. Newswise distribution and news archive system aligns with the interest of communications officers who want to have their information stored and delivered through the most effective platform available.

Cancer is a medical topic that automatically interests a large sector of people. In addition to the communications and media community, the public is profoundly interested and motivated to stay informed because of the number of people who are personally affected by the disease. Newswise offers these consumers information directly from the source. The archive of news provides an even more valuable resource for the public, because they are interested to find research relevant to their individual situation.

"We see this as an important service to the community," says Roger Johnson, Newswise President. "We want to serve the needs of journalists, communicators, and public users, and we can do that by offering curated, highly credible and peer-reviewed cancer research in one place. Newswise works with research institutions to provide the raw materials for tomorrow's news. With the help of NCI and other contributors, we hope to continue developing the Cancer News Source and building on this structure to further serve our community."

Source: Newswise

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Immunotherapy timing key to survival in small cell lung cancer treatment